Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients

Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(3):135-136. doi: 10.1093/ehjcvp/pvaa028.

Authors

Domenico Acanfora¹, Marco Matteo Ciccone², Pietro Scicchitano^{2

3}, Chiara Acanfora^{1

4}, Gerardo Casucci¹

Affiliations

¹ Unit of Internal Medicine, San Francesco Hospital, Viale Europa 21, 82037 Telese Terme (BN), Italy.
² Section of Cardiovascular Diseases, Department of Emergency and Organ Transplantation, University of Bari, School of Medicine, Bari, Italy.
³ Cardiology Unit, Hospital 'F. Perinei' ASL BA, Altamura, Bari, Italy.
⁴ Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.

No abstract available

Publication types

Comment

MeSH terms

Aminobutyrates
Angiotensin Receptor Antagonists
Animals
Apolipoproteins
Betacoronavirus
Biphenyl Compounds
COVID-19
Coronavirus Infections
Drug Combinations
Humans
Inflammation
Mice
Neprilysin
Pandemics
Plaque, Atherosclerotic*
Pneumonia, Viral
SARS-CoV-2
Severe acute respiratory syndrome-related coronavirus*
Tetrazoles
Valsartan

Substances

Aminobutyrates
Angiotensin Receptor Antagonists
Apolipoproteins
Biphenyl Compounds
Drug Combinations
Tetrazoles
Valsartan
Neprilysin
sacubitril and valsartan sodium hydrate drug combination